Activating oncogenic mutations in epidermal growth factor receptor (EGFR) are detected in up to 20% of lung adenocarcinomas (LuADCs) and are the most relevant predictor markers of response to EGFR-tyrosine kinase inhibitors (TKIs). This evidence concerns the gene EGFR and lung adenocarcinoma.